PMID- 38265696
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240127
IS  - 2090-911X (Electronic)
IS  - 1110-2608 (Print)
IS  - 1110-2608 (Linking)
VI  - 76
IP  - 1
DP  - 2024 Jan 24
TI  - Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis 
      and subgroup analyses of reduced and preserved ejection fraction.
PG  - 6
LID - 10.1186/s43044-024-00437-x [doi]
LID - 6
AB  - BACKGROUND: Soluble guanylate cyclase (sGC) stimulators have been investigated 
      for heart failure (HF) in several randomized controlled trials (RCTs). However, 
      its place in the management guidelines of either HFrEF or HfpEF is still 
      inconclusive. METHODS: We conducted a network meta-analysis synthesizing RCTs 
      investigating sGC for HF management, which were retrieved by systematically 
      searching five databases until January 24th, 2023. Dichotomous outcomes were 
      pooled using risk ratio (RR) along with confidence interval (CI). RESULTS: Eight 
      RCTs with a total of 7307 patients were included. Vericiguat 10 mg significantly 
      reduced the composite cardiovascular (CVS) mortality and HF hospitalization in HF 
      (RR: 0.88, 95% CI [0.79; 0.98]) and in HFrEF (RR: 0.87, 95% CI [0.78; 0.97]); 
      however, it was not effective in HFpEF (RR: 0.69, 95% CI [0.15; 3.05]). Also, 
      vericiguat 10 mg showed no difference compared to placebo regarding the incidence 
      of all-cause mortality (RR: 0.96, 95% CI [0.84; 1.10]), any adverse events (AEs) 
      (RR: 0.94, 95% CI [0.83; 1.07]), any serious AEs (RR: 0.91, 95% CI [0.81; 1.01]), 
      and any AEs leading to drug discontinuation (RR: 1.14, 95% CI [0.92; 1.40]). 
      CONCLUSION: Vericiguat 10 mg was effective in reducing the composite CVS 
      mortality and HF hospitalization, with an acceptable safety profile. This was 
      only observed in HFrEF patients, but not in HFpEF patients. However, our data 
      regarding other agents (riociguat and praliciguat) and HFpEF can be underpowered, 
      warranting further RCTs to clarify vericiguat 10 mg place in HFrEF management 
      guidelines and to investigate sGC stimulators for HFpEF in large-scale trials.
CI  - (c) 2024. The Author(s).
FAU - Abuelazm, Mohamed T
AU  - Abuelazm MT
AUID- ORCID: 0000-0002-2514-0689
AD  - Faculty of Medicine, Tanta University, Tanta, Egypt. Dr.mabuelazm@gmail.com.
FAU - Attia, Abdelrahman
AU  - Attia A
AD  - Faculty of Medicine, Cairo University, Cairo, Egypt.
FAU - Abdelnabi, Mohamed
AU  - Abdelnabi M
AD  - Department of Clinical Pharmacy, University of Michigan, Ann Arbor, MI, USA.
FAU - Jafar, Uzair
AU  - Jafar U
AD  - Department of Medicine, King Edward Medical University, Lahore, Pakistan.
FAU - Almaadawy, Omar
AU  - Almaadawy O
AD  - Department of Internal Medicine, MedStar Health, Baltimore, MD, USA.
FAU - Elzeftawy, Mohamed A
AU  - Elzeftawy MA
AD  - Faculty of Medicine, Tanta University, Tanta, Egypt.
FAU - Mahmoud, Abdelrahman
AU  - Mahmoud A
AD  - Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Albakri, Khaled
AU  - Albakri K
AD  - Faculty of Medicine, Hashemite University, Zarqa, Jordan.
FAU - Abdelazeem, Basel
AU  - Abdelazeem B
AD  - Department of Cardiology, West Virginia University, Morgantown, WV, USA.
LA  - eng
PT  - Journal Article
DEP - 20240124
PL  - Germany
TA  - Egypt Heart J
JT  - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of 
      Cardiology
JID - 9106952
PMC - PMC10808080
OTO - NOTNLM
OT  - Heart failure
OT  - Meta-analysis
OT  - Review
OT  - Riociguat
OT  - Soluble guanylate cyclase stimulators
OT  - Vericiguat
OT  - sGC stimulator
COIS- The authors declare no conflict of interest.
EDAT- 2024/01/24 12:43
MHDA- 2024/01/24 12:44
PMCR- 2024/01/24
CRDT- 2024/01/24 11:14
PHST- 2023/10/06 00:00 [received]
PHST- 2024/01/13 00:00 [accepted]
PHST- 2024/01/24 12:44 [medline]
PHST- 2024/01/24 12:43 [pubmed]
PHST- 2024/01/24 11:14 [entrez]
PHST- 2024/01/24 00:00 [pmc-release]
AID - 10.1186/s43044-024-00437-x [pii]
AID - 437 [pii]
AID - 10.1186/s43044-024-00437-x [doi]
PST - epublish
SO  - Egypt Heart J. 2024 Jan 24;76(1):6. doi: 10.1186/s43044-024-00437-x.